Accueil   Diary - News   All news Two new projects accredited by Lyonbiopole, selected by SFI

Two new projects accredited by Lyonbiopole, selected by SFI

After Lyonbiopole’s accreditation, two collaborative projects were selected as part of the 23rd SFII call. The Oncochip 3D project, co-accredited by Minalogic competitiveness cluster, addresses the development of bio-printed and microstructured chips for R&D in oncology. The NGS-IVS project aims to develop a new diagnostic tool for erythrocytic genotyping. These two projects will benefit from public funding from the French State, local authorities and FEDER European funds.

 

FOCUS ON THIS PROJECTS

 

Project 3D ONCOCHIP

DEVELOPMENT OF BIO-PRINTED AND MICROSTRUCTURED CHIPS WITH MICROTUMORS FOR HIGH - SPEED SCREENING AND ONCOLOGY RESEARCH AND DEVELOPMENT.

 

Partners: CTIBIOTECH (coordinator) (69), Microlight3D (38), Grenoble INP - Laboratoire Jean Kuntzmann (38), CNRS - Laboratoire des matériaux et du génie physique (LMGP) (38) 

The aim of the 3D-ONCOCHIP project is to create microtumor chips using complementary technologies of 3D bioprinting (laser micro-printing and bio-extrusion of cells) for 4 therapeutic targets: breast, ovarian, pancreatic and prostate cancer. The microtumor chips will reproduce in vitro and in 3D the patients' tumor environment as a powerful and reproducible human biological model to address the market of personalized medicine against cancer and fasttrack the development of chemotherapies and immunotherapies.

 

Budget: 2.2M€

Accreditations: Lyonbiopole and Minalogic

 

Project NGS-IVD

NEXT–GEN SEQUENCING FOR IVD: MASSIVELY PARALLEL AND MULTIPLEX DIAGNOSTIC

 

Partners: AXO Science, Viroscan 3D, ProfileXpert, Inserm UMR1078 – EFS Bretagne

 

The NGS-IVD project aims at developing a new IVD product responding to the problematic of blood group genotyping and allowing to override the disadvantages of traditional genotyping tests that are currently commercialized. This product will associate the targeting of genes responsible for blood group polymorphisms by multiplex PCR with an analysis of PCR products thanks to the power of next generation sequencing techniques. This project includes 4 main steps: development of a new genomic DNA extraction method, creation of an index library allowing the analysis of until 1,000 trials simultaneously, the optimization of multiplex PCR for the subsequent analysis by sequencing, and the development of a software/interface allowing data extraction, automated analysis and report creation. In the future, NGS-IVD technology would then be extended to development of kits for the caracterization of pathologies requiring targeted and accurate DNA profiling (trisomy 21, K-Ras cancerology, BRAF p53 mutations…).

 

Budget: 1.7 M€

Accreditations: Lyonbiopole

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree